Reata Announces Presentations at the 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)
An oral presentation will discuss molecular insights into the effects of bardoxolone in cellular models of polycystic kidney disease (PKD), including data demonstrating that bardoxolone reduces cyst formation in cellular models of PKD. The poster presentations will include baseline characteristics for the Phase 3 portion of CARDINAL, a Phase 2/3 study of bardoxolone for the treatment of Alport syndrome, and safety and efficacy data from the Phase 2 PHOENIX study of bardoxolone in patients with rare forms of CKD. One
Abstracts to be presented are summarized below.
Title: The Nrf2 Activator Bardoxolone Methyl Inhibits Cyst Formation, Reduces Inflammation, and Improves Mitochondrial Function in Cellular Models of Polycystic Kidney Disease
Presenter:
Oral:
Title: Baseline Characteristics in the “CARDINAL” Trial: A Phase 3 Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome
Presenter: Bertrand Knebelmann, M.D., Division de Néphrologie, Hôpital Necker, Assistance Publique-Hôpitaux de
Poster FP179: Friday, June 14th,
Title: Safety and Efficacy of Bardoxolone Methyl in Patients with Rare Chronic Kidney Diseases
Presenter:
Poster FP117: Friday, June 14th,
Title: Safety and Efficacy of Bardoxolone Methyl in Patients with Focal Segmental Glomerulosclerosis
Presenter:
Poster FP152:
About Bardoxolone
Bardoxolone is an experimental, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote restoration of mitochondrial function, reduction of oxidative stress, and inhibition of pro-inflammatory signaling.
About
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes restoration of mitochondrial function, reduction of oxidative stress, and inhibition of pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (iv) other factors set forth in Reata’s filings with the
Contact:
(972) 865-2219
https://www.reatapharma.com
Investors:
Vice President, Strategy
(469) 374-8721
ir@reatapharma.com
Media:
Matt Middleman, M.D.
LifeSci Public Relations
(646) 627-8384
matt.middleman@lifescipublicrelations.com
Source: Reata Pharmaceuticals, Inc.